Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models

Simone Göschl, Ekaterina Schreiber-Brynzak, Verena Pichler, Klaudia Cseh, Petra Heffeter, Ute Jungwirth, Michael A Jakupec, Walter Berger, Bernhard K Keppler

Research output: Contribution to journalArticlepeer-review

51 Citations (SciVal)


Using platinum(iv) prodrugs of clinically established platinum(ii) compounds is a strategy to overcome side effects and acquired resistances. We studied four oxaliplatin-derived platinum(iv) complexes with varying axial ligands in various in vitro and in vivo settings. The ability to interfere with DNA (pUC19) in the presence and absence of a reducing agent (ascorbic acid) was investigated in cell-free experiments. Cytotoxicity was compared under normoxic and hypoxic conditions in monolayer cultures and multicellular spheroids of colon carcinoma cell lines. Effects on the cell cycle were investigated by flow cytometry, and the capacity of inducing apoptosis was confirmed by flow cytometry and Western blotting. The anti-cancer activity of one complex was studied in vivo in immunodeficient and immunocompetent mice, and the platinum levels in various organs and the tumor after treatment were quantified. The results demonstrate that modification of the axial ligands can improve the cytotoxic potency. The complexes are able to interfere with plasmid DNA, which is enhanced by co-incubation with a reducing agent, and cause cell cycle perturbations. At higher concentrations, they induce apoptosis, but generate only low levels of reactive oxygen species. Two of the complexes increase the life span of leukemia (L1210) bearing mice, and one showed effects similar to oxaliplatin in a CT26 solid tumor model, despite the low platinum levels in the tumor. As in the case of oxaliplatin, activity in the latter model depends on an intact immune system. These findings show new perspectives for the development of platinum(iv) prodrugs of the anticancer agent oxaliplatin, combining bioreductive properties and immunogenic aspects.

Original languageEnglish
Pages (from-to)309-322
Number of pages14
Issue number3
Early online date16 Feb 2017
Publication statusPublished - 22 Mar 2017


  • Animals
  • Antineoplastic Agents/pharmacology
  • Apoptosis/drug effects
  • Cell Cycle/drug effects
  • Cell Proliferation/drug effects
  • Cisplatin/pharmacology
  • Colonic Neoplasms/drug therapy
  • Humans
  • In Vitro Techniques
  • Leukemia L1210/drug therapy
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred DBA
  • Mice, SCID
  • Organoplatinum Compounds/pharmacology
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays


Dive into the research topics of 'Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models'. Together they form a unique fingerprint.

Cite this